Matches in SemOpenAlex for { <https://semopenalex.org/work/W103259726> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W103259726 endingPage "26" @default.
- W103259726 startingPage "612" @default.
- W103259726 abstract "This review summarizes data on currently used antiobesity drugs and new compounds under clinical development. Three antiobesity drugs are currently accepted for long-term use. Sibutramine is a noradrenaline and serotonin reuptake inhibitor which reduces body weight by about 4-5 kg but increases heart rate and arterial blood pressure. Orlistat is a gastrointestinal lipase inhibitor which results in mean weight loss by about 3 kg and reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance; however, adverse gastrointestinal effects have been observed. Rimonabant is an endocannabinoid CB1 receptor antagonist which induces a 4-5 kg mean weight loss and improves glycemic and lipid profiles, but it induces anxiety and depressive disorders. Unfortunately, there are no data on the chronic administration of these drugs. Other drugs can induce weight loss, e.g. some antidepressants, antiseizure agents, and antidiabetic drugs. The moderate efficacy of currently used antiobesity drugs has led to an intense effort to identify new, safe antiobesity drugs with better therapeutic profiles. The new antiobesity drugs under clinical development include: 1) agents that affect neurotransmitters in the central nervous system, including noradrenaline and dopamine reuptake inhibitors (bupropion, radafaxine), selective 5HT2C receptor agonists (lorcaserin), and selective 5HT6 receptor antagonists, 2) agents that modulate the activity of neuropeptides influencing food intake, including leptin analogues, human ciliary neurotrophic factor (Axokine), neuropeptide Y antagonists, and melanine-concentrating hormone antagonists, 3) agents that affect the peripheral satiety signals and brain-gut axis, e.g. selective cholecystokinin receptor A agonists, PYY3-36, agents decreasing ghrelin activity, 4) thermogenic agents, e.g. selective beta3 receptor agonists and selective thyroid hormone receptor beta agonists, and 5) others, e.g. human growth hormone fragment (AOD9604) and gastrointestinal lipase inhibitor (cetilistat)." @default.
- W103259726 created "2016-06-24" @default.
- W103259726 creator A5050060343 @default.
- W103259726 date "2007-10-19" @default.
- W103259726 modified "2023-09-24" @default.
- W103259726 title "[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]." @default.
- W103259726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17971763" @default.
- W103259726 hasPublicationYear "2007" @default.
- W103259726 type Work @default.
- W103259726 sameAs 103259726 @default.
- W103259726 citedByCount "5" @default.
- W103259726 countsByYear W1032597262015 @default.
- W103259726 countsByYear W1032597262017 @default.
- W103259726 countsByYear W1032597262019 @default.
- W103259726 crossrefType "journal-article" @default.
- W103259726 hasAuthorship W103259726A5050060343 @default.
- W103259726 hasConcept C126322002 @default.
- W103259726 hasConcept C134018914 @default.
- W103259726 hasConcept C148001335 @default.
- W103259726 hasConcept C170493617 @default.
- W103259726 hasConcept C2776433454 @default.
- W103259726 hasConcept C2776885963 @default.
- W103259726 hasConcept C2777180221 @default.
- W103259726 hasConcept C2777646958 @default.
- W103259726 hasConcept C511355011 @default.
- W103259726 hasConcept C544821477 @default.
- W103259726 hasConcept C555293320 @default.
- W103259726 hasConcept C71924100 @default.
- W103259726 hasConcept C98274493 @default.
- W103259726 hasConceptScore W103259726C126322002 @default.
- W103259726 hasConceptScore W103259726C134018914 @default.
- W103259726 hasConceptScore W103259726C148001335 @default.
- W103259726 hasConceptScore W103259726C170493617 @default.
- W103259726 hasConceptScore W103259726C2776433454 @default.
- W103259726 hasConceptScore W103259726C2776885963 @default.
- W103259726 hasConceptScore W103259726C2777180221 @default.
- W103259726 hasConceptScore W103259726C2777646958 @default.
- W103259726 hasConceptScore W103259726C511355011 @default.
- W103259726 hasConceptScore W103259726C544821477 @default.
- W103259726 hasConceptScore W103259726C555293320 @default.
- W103259726 hasConceptScore W103259726C71924100 @default.
- W103259726 hasConceptScore W103259726C98274493 @default.
- W103259726 hasLocation W1032597261 @default.
- W103259726 hasOpenAccess W103259726 @default.
- W103259726 hasPrimaryLocation W1032597261 @default.
- W103259726 hasRelatedWork W119750789 @default.
- W103259726 hasRelatedWork W1523663430 @default.
- W103259726 hasRelatedWork W1550334731 @default.
- W103259726 hasRelatedWork W1591352723 @default.
- W103259726 hasRelatedWork W1927710737 @default.
- W103259726 hasRelatedWork W1984117026 @default.
- W103259726 hasRelatedWork W1988047564 @default.
- W103259726 hasRelatedWork W2026330215 @default.
- W103259726 hasRelatedWork W2028243859 @default.
- W103259726 hasRelatedWork W2065547659 @default.
- W103259726 hasRelatedWork W2118152671 @default.
- W103259726 hasRelatedWork W2125309270 @default.
- W103259726 hasRelatedWork W2338141595 @default.
- W103259726 hasRelatedWork W2372652453 @default.
- W103259726 hasRelatedWork W2387834372 @default.
- W103259726 hasRelatedWork W2415553370 @default.
- W103259726 hasRelatedWork W96089151 @default.
- W103259726 hasRelatedWork W181936933 @default.
- W103259726 hasRelatedWork W3103785689 @default.
- W103259726 hasRelatedWork W963333929 @default.
- W103259726 hasVolume "61" @default.
- W103259726 isParatext "false" @default.
- W103259726 isRetracted "false" @default.
- W103259726 magId "103259726" @default.
- W103259726 workType "article" @default.